Formycon Gets Date For Aflibercept Filing In US
US FDA Offers June 2024 Action Date For Coherus-Partnered FYB203 Eylea Biosimilar
Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.
